Back to Screener

Satellos Bioscience Inc. - Common Stock (MSLE)

NASDAQ Micro Cap

Healthcare › Biotechnology

$7.17
Market Cap: $111M
Data as of Dec 31, 2025

Price History

Apr 8, 2026 — May 15, 2026

Investment Snapshot

  • P/B of 3.99 — trading above book value
  • Piotroski F-Score 1/9 — signs of financial weakness
  • Loss-making — negative ROE of -89.5%

Satellos Bioscience Inc. - Common Stock (MSLE) is a Healthcare company operating in Biotechnology, listed on the NASDAQ , with a market capitalisation of $111 million . Key value metrics: P/B ratio 3.99, Piotroski F-Score 1 out of 9 .

Value Score

Key Metrics

P/E Ratio
3.99
EPS
$-1.61
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Satellos Bioscience Inc. - Common Stock — Fundamental Analysis Summary

On financial health, MSLE shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -89.5% (sector average: -20.6%).

StockPik's composite Value Score for MSLE is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

MSLE shows earnings declining at 21%.

Top Value Stocks in Healthcare

Symbol Price P/E Score
EMBC $3.90 2.1 100
HCM $13.31 5.1 100
GMAB $27.06 1.8 100
CGEN $2.71 7.3 100
INVA $22.89 5.8 100
How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
MSIF
Next
MSM